The American Antitrust Institute (AAI) has announced its selection of leading legal practitioners and economists to be recognized at the AAI 2016 Antitrust Enforcement Awards. The Honorees will be featured at a gala awards dinner on Wednesday, November 9, 2016 following the AAI’s Annual Private Antitrust Enforcement Conference. Registration and program information for the conference and the awards dinner is available here.
The American Antitrust Institute has published the agenda for its 10th Annual Private Antitrust Enforcement Conference, which will be held on Wednesday, November 9, 2016, at the National Press Club in Washington, D.C.
On Wednesday, November 9, 2016, the American Antitrust Institute will host its 10th Annual Private Antitrust Enforcement Conference at the National Press Club in Washington D.C. Following the conference, the AAI will host its 4th Annual Antitrust Enforcement Awards Dinner at the JW Marriott Hotel.
On October 6, join CCIA and the AAI for a luncheon event featuring a special keynote address from FTC Chairwoman Edith Ramirez as she speaks about the agency’s recent work at the intersection of intellectual property and antitrust, including patents.
Neither U.S. antitrust nor other domestic law seems to provide a realistic remedy for a firm’s abuse of its superior bargaining position (ASBP) vis a vis another, positionally weaker firm, in the absence of recognized market power. Several of our major trading partners do have such a provision in their competition laws and there is enough to be learned from their experience and from investigations by academics and international institutions to warrant a careful examination of this gap in the regulation of vertical relationships to determine how such a provision could be made to work within a distinctively American framework.
This paper by AAI Founder and Senior Fellow Bert Foer advocates a process for the FTC to undertake, beginning with empirical data collection.
The American Antitrust Institute (AAI) filed comments today in response to a request by the Antitrust Division (DOJ) and the Federal Trade Commission (FTC) for public comment on the agencies’ proposed update of the DOJ/FTC Antitrust Guidelines for the Licensing of Intellectual Property.
AAI President Diana Moss testified at the Senate Judiciary Committee hearing on consolidation in the U.S. seed and agrochemical industry on September 20, 2016. Dr. Moss’s testimony reflects the AAI's long history of research, education, and advocacy on competition in agriculture and food.
AAI President Diana Moss spoke recently at two separate events on airline and healthcare competition.
AAI’s Associate General Counsel Randy Stutz recently spoke at the 9th Seoul International Competition Forum in Seoul, Korea. The Seoul International Competition Forum is a biannual, global conference sponsored by the Korea Fair Trade Competition. Top government officials, competition experts from international organizations, and practitioners, academics, and others convened to discuss diverse subjects relating to competition law and policy. Stutz participated in the morning panel on aftermarkets and delivered remarks on Effective Policing of Aftermarket Restraints Involving Intellectual Property.
Public debate over the pricing of important drugs is gaining traction in the wake of the EpiPen controversy. The AAI has collected resources here on key competition issues surrounding branded and generic drugs. Mergers of branded and generic drug companies and strategic anticompetitive conduct by pharmaceutical companies can affect drug prices, choices, and innovation in these important markets, with direct and significant effects on consumers.
AAI’s resources on pharmaceutical competition range from a documentary film on generic drug manufacturer Mylan’s past conduct involving an anti-anxiety drug to analysis supporting opposition to the recently approved Teva-Allergan merger. Also included are certain AAI amicus briefs filed in federal court cases that unpack key issues surrounding the use of patent rights to shape and control competition. This legal-economic analysis covers strategic attempts to delay the entry of generic drugs (“pay-for-delay”) and to move consumers from older-generation drugs coming off patent to next generation branded drugs (“product-hopping”).